WebMar 1, 1998 · Vinblastine/cisplatin and etoposide/cisplatin were the most cost-effective regimens. Both increased average survival by 0.27 years while decreasing the cost per case by $2,865 and $1,418, respectively. Vinorelbine alone increased survival relative to BSC, while saving $1,014 per case. WebThe average total cost of six cycles CP was 13,250 USD while the average cost of cisplatin alone was 14,573 USD. The highest average cost for six cycles was for GC at 33,559 USD. With cisplatin/paclitaxel being the most effective, the cost effectiveness analysis showed that cisplatin, CT, GC, and VC were all dominated by CP.
Costs associated with intravenous chemotherapy administration in ...
WebEspecially for the paclitaxel and cisplatin (TP) regimen, has a lower incidence of radiation esophagitis and better tolerance and convenience compared with the classic PF regimen. 8 , 10 , 12 ... and the cost is high. The application of esophagograms to evaluate early curative effects has a long history in China and has accumulated a lot of ... WebCisplatin (DDP) is a common therapeutic option for non-small cell lung carcinoma (NSCLC). However, some patients fail to respond to the DDP chemotherapy. ... nanoparticles, zinc oxide nano-zinc carriers are low-cost, easily available, multifunctional inorganic nanomaterials that can be produced on a large scale. In addition, zinc oxide nano ... python teams チャット 取得
Cost-Effectiveness of Vinorelbine Alone or Vinorelbine Plus …
WebJul 9, 2024 · Introduction This study aimed to evaluate the cost-effectiveness of cisplatin plus gemcitabine vs. paclitaxel plus gemcitabine as a first-line treatment for metastatic triple-negative breast cancer in China. Methods The Markov model and partitioned survival (PS) model were used, and the study included three health states over the period of a … WebCisplatin-induced kidney toxicity is reviewed here. The use of cisplatin in patients with pre-existing kidney dysfunction and the kidney effects of the platinum analogs, carboplatin … WebAs administered in the trial, paclitaxel/cisplatin cost $76,370 per life-year gained (LYG) and paclitaxel/cisplatin/G-CSF $138,578 per LYG relative to etoposide/cisplatin. However, when modelled as an outpatient 3-h infusion, paclitaxel/cisplatin was moderately cost-effective at $30,619 per LYG. When compared with historical controls treated ... python teams 連携 excel表